The question lands in nearly every prescriber's office: tirzepatide vs semaglutide, which one works better? A large June 2026 meta-analysis finally pooled the head-to-head evidence, and the answer is clearer than it has ever been. Tirzepatide, sold as Mounjaro and Zepbound, lost more weight than semaglutide, sold as Ozempic and Wegovy. But "more weight" is not the same as "better for you," and the gap between those two statements is where the real decision lives.
What happened
Researchers gathered 28 randomised controlled trials covering roughly 34,300 patients and compared the two medicines directly, as reported by The Hill. Pooled across the studies, tirzepatide produced around 15 to 20 percent total body weight loss, against roughly 12 to 13 percent for semaglutide. On average, people on tirzepatide lost about 4.6 percent more of their body weight.
The single cleanest comparison comes from the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in May 2025. Over 72 weeks, tirzepatide delivered 20.2 percent weight loss versus 13.7 percent for semaglutide. Roughly 32 percent of the tirzepatide group lost at least a quarter of their body weight, against 16 percent on semaglutide.
Why a bigger number is not the whole story
Weight is one outcome, and it is the loudest one. It is not the only one that matters.
Semaglutide carries the longer track record and, for many women, the easier path to access and refills. It also holds the stronger cardiovascular and kidney evidence so far. The SELECT trial showed a 20 percent reduction in major cardiac events in people with overweight or obesity and existing heart disease, and the FLOW kidney trial showed slowed kidney decline in type 2 diabetes. Those are hard endpoints, the kind that change lives, not just dress sizes.
There is also the matter of what the scale does not show. Both drugs are appetite-quieting, which means both can quietly take muscle along with fat if protein and resistance training slip. A faster drop is not automatically a healthier one. The headline figure says nothing about your energy, your bone density, or whether you can hold the result for years.
What it means for you
The honest takeaway: the strongest medicine on paper is not always the strongest medicine for you. The best GLP-1 is the one you tolerate, the one you can actually get and afford month after month, and the one you stay on long enough for it to work. A drug you abandon at week ten because of nausea or a supply gap loses to one you keep taking for two years.
Bring this evidence to your prescriber as a starting point, not a verdict. Your heart history, your kidney function, your side effect pattern, and your access all belong in that conversation. If you are weighing the specific brands, our deeper look at tirzepatide vs semaglutide and the practical Mounjaro vs Wegovy comparison walk through the trade-offs. And whichever you choose, protecting muscle on a GLP-1 is the work that turns a number on the scale into a body that feels steady.
What Steady does with this
Steady tracks what the meta-analysis cannot: your symptoms across 14 GLP-1 side effects, your protein and strength sessions, your weight trend read against your cycle, and your dose timeline. When you sit down with your prescriber to discuss whether to switch or stay, Steady turns the whole month into one clear page, so the choice between tirzepatide and semaglutide is yours to make with real evidence in hand.
